氨酸:呼吸道疾病的潜在治疗剂
Meng Li1, Xinru Gu1, Jiaming Yang2
1School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
European journal of pharmacology
|May 5, 2025
概括
素是一种天然的黄胺,在治疗COVID-19和肺癌等呼吸道疾病方面表现有前途. 它通过各种分子途径对抗炎症和氧化应激,提供了一个新的治疗途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 呼吸道疾病对全球的健康造成重大负担.
- 自然衍生化合物正在获得治疗应用的关注.
- 素 (Lut) 是一种黄类化合物,表现出多种药理活性.
研究的目的:
- 在呼吸系统疾病中全面审查卢泰林的治疗作用和机制.
- 为了检查Luteolin的物理化学特性,毒性和作用途径.
- 为开发基于素的呼吸道疗法提供见解.
主要方法:
- 关于素在呼吸系统疾病中的作用的文献综述.
- 分析了luteolin的药理活动 (抗炎,抗氧化,抗质).
- 检查素准的分子通路.
主要成果:
- 氨酸表现出与呼吸道疾病相关的抗炎,抗氧化和抗质性质.
- 氨酸调节关键信号通路,包括NF-κB,Nrf2,MAPK,JAK/STAT和PI3K/AKT.
- 氨酸抑制炎症媒介,减少氧化应激,并诱导肺癌细胞的亡.
结论:
- 氨酸对各种呼吸系统疾病具有显著的治疗潜力.
- 了解素的机制可以指导新疗法的开发.
- 对素的进一步研究可能会导致对呼吸道疾病的新药开发.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
163
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
163
Drugs Used in Lower Respiratory Disorders: Overview
260
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
260
COPD: Management Using Bronchodilators and Corticosteroids
133
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
133
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
167
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
167
Drugs Used in Upper Respiratory Disorders: Overview
139
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
139
Acute Respiratory Failure-V
110
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
110


